| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
867 Stock Overview
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.
Rewards
Risk Analysis
No risks detected for 867 from our risk checks.
China Medical System Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$13.78 |
| 52 Week High | HK$14.80 |
| 52 Week Low | HK$8.54 |
| Beta | 0.77 |
| 1 Month Change | 41.92% |
| 3 Month Change | 25.50% |
| 1 Year Change | 3.77% |
| 3 Year Change | 20.88% |
| 5 Year Change | -22.67% |
| Change since IPO | 358.11% |
Recent News & Updates
Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14
China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Recent updates
Is China Medical System Holdings (HKG:867) Using Too Much Debt?
Sep 14China Medical System Holdings (HKG:867) Is Paying Out A Larger Dividend Than Last Year
Aug 25Do China Medical System Holdings' (HKG:867) Earnings Warrant Your Attention?
Aug 15An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 49% Undervalued
Jul 08Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
May 16Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Apr 10China Medical System Holdings (HKG:867) Is Increasing Its Dividend To HK$0.28
Mar 22If You Like EPS Growth Then Check Out China Medical System Holdings (HKG:867) Before It's Too Late
Feb 09Does China Medical System Holdings (HKG:867) Have A Healthy Balance Sheet?
Dec 25Should You Be Adding China Medical System Holdings (HKG:867) To Your Watchlist Today?
Nov 10China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Sep 25China Medical System Holdings' (HKG:867) Dividend Will Be Increased To HK$0.32
Aug 26Here's Why We Think China Medical System Holdings (HKG:867) Is Well Worth Watching
Jul 30An Intrinsic Calculation For China Medical System Holdings Limited (HKG:867) Suggests It's 33% Undervalued
Jun 27China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Jun 14Does China Medical System Holdings (HKG:867) Deserve A Spot On Your Watchlist?
Apr 20Is There An Opportunity With China Medical System Holdings Limited's (HKG:867) 43% Undervaluation?
Mar 25Shareholders Are Loving China Medical System Holdings Limited's (HKG:867) 3.0% Yield
Mar 08Here's What China Medical System Holdings Limited's (HKG:867) Shareholder Ownership Structure Looks Like
Feb 09China Medical System Holdings' (HKG:867) Shareholders Are Down 45% On Their Shares
Jan 19Is China Medical System Holdings Limited's (HKG:867) Latest Stock Performance Being Led By Its Strong Fundamentals?
Dec 30
Have Insiders Been Buying China Medical System Holdings Limited (HKG:867) Shares?
Dec 16China Medical System Holdings (HKG:867) Could Easily Take On More Debt
Dec 01There's Reason For Concern Over China Medical System Holdings Limited's (HKG:867) Price
Jul 28You Have To Love China Medical System Holdings Limited's (HKG:867) Dividend
Jul 16How Much Is China Medical System Holdings Limited (HKG:867) Paying Its CEO?
Jul 01Shareholder Returns
| 867 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 21.5% | 0.02% | 0.3% |
| 1Y | 3.8% | -7.8% | -21.2% |
Return vs Industry: 867 exceeded the Hong Kong Pharmaceuticals industry which returned -7.8% over the past year.
Return vs Market: 867 exceeded the Hong Kong Market which returned -21.2% over the past year.
Price Volatility
| 867 volatility | |
|---|---|
| 867 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.1% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 867 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 867's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 5,454 | Kong Lam | https://www.cms.net.cn |
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company’s products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn’s disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications.
China Medical System Holdings Limited Fundamentals Summary
| 867 fundamental statistics | |
|---|---|
| Market Cap | HK$34.33b |
| Earnings (TTM) | HK$3.56b |
| Revenue (TTM) | HK$9.99b |
9.5x
P/E Ratio3.4x
P/S RatioIs 867 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 867 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.94b |
| Cost of Revenue | CN¥2.13b |
| Gross Profit | CN¥6.81b |
| Other Expenses | CN¥3.62b |
| Earnings | CN¥3.19b |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.30 |
| Gross Margin | 76.15% |
| Net Profit Margin | 35.66% |
| Debt/Equity Ratio | 12.7% |
How did 867 perform over the long term?
See historical performance and comparison